SU880252A3 - Способ получени 1,2,3,5-тетрагидроимидазотиенопиримидин-2-онов или их солей - Google Patents
Способ получени 1,2,3,5-тетрагидроимидазотиенопиримидин-2-онов или их солей Download PDFInfo
- Publication number
- SU880252A3 SU880252A3 SU792798503A SU2798503A SU880252A3 SU 880252 A3 SU880252 A3 SU 880252A3 SU 792798503 A SU792798503 A SU 792798503A SU 2798503 A SU2798503 A SU 2798503A SU 880252 A3 SU880252 A3 SU 880252A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- carbon atoms
- compounds
- atom
- alkyl group
- salts
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 6
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 5
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 4
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 4
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 4
- 239000003146 anticoagulant agent Substances 0.000 abstract description 2
- 229960004676 antithrombotic agent Drugs 0.000 abstract description 2
- 210000001772 blood platelet Anatomy 0.000 abstract description 2
- 230000002744 anti-aggregatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- PNLDBSNRSSNUAA-UHFFFAOYSA-N 2-chloro-5,6-dimethyl-1,4-dihydrothieno[2,3-d]pyrimidine Chemical compound N1=C(Cl)NCC2=C1SC(C)=C2C PNLDBSNRSSNUAA-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- -1 2-chloro-3-ethoxycarbonylmethyl-5,6-dimethylquinazoline Chemical compound 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- LDXCWOSUWRNYEW-UHFFFAOYSA-N 2,4-dichloro-5,6-dimethylthieno[2,3-d]pyrimidine Chemical compound ClC1=NC(Cl)=C2C(C)=C(C)SC2=N1 LDXCWOSUWRNYEW-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- IAVAUMSRZIHIMD-UHFFFAOYSA-N C(C=CC(=O)O)(=O)O.C(C=C/C(=O)O)(=O)O.C(CCC(=O)O)(=O)O Chemical compound C(C=CC(=O)O)(=O)O.C(C=C/C(=O)O)(=O)O.C(CCC(=O)O)(=O)O IAVAUMSRZIHIMD-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- ZXVOCOLRQJZVBW-UHFFFAOYSA-N azane;ethanol Chemical compound N.CCO ZXVOCOLRQJZVBW-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9783278A JPS5527105A (en) | 1978-08-11 | 1978-08-11 | Imidazothienopyrimidinones compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU880252A3 true SU880252A3 (ru) | 1981-11-07 |
Family
ID=14202683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU792798503A SU880252A3 (ru) | 1978-08-11 | 1979-08-10 | Способ получени 1,2,3,5-тетрагидроимидазотиенопиримидин-2-онов или их солей |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4284773A (enExample) |
| EP (1) | EP0008408B1 (enExample) |
| JP (1) | JPS5527105A (enExample) |
| AU (1) | AU529068B2 (enExample) |
| CA (1) | CA1116597A (enExample) |
| CS (1) | CS219256B2 (enExample) |
| DE (1) | DE2961552D1 (enExample) |
| DK (1) | DK153844C (enExample) |
| ES (1) | ES483289A1 (enExample) |
| GR (1) | GR73839B (enExample) |
| IL (1) | IL57923A (enExample) |
| MX (1) | MX6242E (enExample) |
| PH (1) | PH15530A (enExample) |
| SU (1) | SU880252A3 (enExample) |
| YU (1) | YU41170B (enExample) |
| ZA (1) | ZA793909B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4287340A (en) * | 1979-08-27 | 1981-09-01 | Warner-Lambert Company | Dihydro-oxo-pyrido[1,2-a]thienopyrimidine compounds |
| ZW11781A1 (en) * | 1980-06-27 | 1982-01-20 | Hoffmann La Roche | Pyrimidine derivatives |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US8304420B2 (en) | 2006-11-28 | 2012-11-06 | Shire Llc | Substituted quinazolines for reducing platelet count |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| GB0808950D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | Substituted quinazolines |
| ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| MX357121B (es) | 2011-03-01 | 2018-06-27 | Synergy Pharmaceuticals Inc Star | Proceso de preparacion de agonistas c de guanilato ciclasa. |
| EP2958577A2 (en) | 2013-02-25 | 2015-12-30 | Synergy Pharmaceuticals Inc. | Guanylate cyclase receptor agonists for use in colonic cleansing |
| EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| PL3004138T3 (pl) | 2013-06-05 | 2024-07-29 | Bausch Health Ireland Limited | Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie |
| CA2920856C (en) | 2013-08-09 | 2026-03-03 | Ardelyx, Inc. | Ph modulating compounds for inhibiting gastrointestinal phosphate uptake |
| JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス， インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3890321A (en) * | 1971-09-20 | 1975-06-17 | Pfizer | 6-aryl-5-ethyl-pyrimidin-4-ol compounds useful as intermediates and bronchodilators |
| US3932407A (en) * | 1973-11-19 | 1976-01-13 | Bristol-Myers Company | Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones |
| DE2411273A1 (de) * | 1974-03-06 | 1975-09-18 | Schering Ag | Neue thieno eckige klammer auf 2,3-d eckige klammer zu pyrimidinone und verfahren zu ihrer herstellung |
-
1978
- 1978-08-11 JP JP9783278A patent/JPS5527105A/ja active Granted
-
1979
- 1979-07-30 IL IL57923A patent/IL57923A/xx unknown
- 1979-07-31 ZA ZA00793909A patent/ZA793909B/xx unknown
- 1979-08-03 PH PH22860A patent/PH15530A/en unknown
- 1979-08-03 CS CS795377A patent/CS219256B2/cs unknown
- 1979-08-08 EP EP79102869A patent/EP0008408B1/en not_active Expired
- 1979-08-08 DE DE7979102869T patent/DE2961552D1/de not_active Expired
- 1979-08-08 CA CA000333380A patent/CA1116597A/en not_active Expired
- 1979-08-09 ES ES483289A patent/ES483289A1/es not_active Expired
- 1979-08-09 AU AU49735/79A patent/AU529068B2/en not_active Ceased
- 1979-08-09 GR GR59809A patent/GR73839B/el unknown
- 1979-08-10 DK DK336779A patent/DK153844C/da not_active IP Right Cessation
- 1979-08-10 SU SU792798503A patent/SU880252A3/ru active
- 1979-08-10 MX MX798313U patent/MX6242E/es unknown
- 1979-08-10 YU YU1947/79A patent/YU41170B/xx unknown
- 1979-08-13 US US06/066,113 patent/US4284773A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE2961552D1 (en) | 1982-02-04 |
| MX6242E (es) | 1985-01-28 |
| JPS5527105A (en) | 1980-02-27 |
| IL57923A0 (en) | 1979-11-30 |
| DK153844C (da) | 1989-01-30 |
| JPS627914B2 (enExample) | 1987-02-19 |
| AU4973579A (en) | 1980-02-14 |
| US4284773A (en) | 1981-08-18 |
| YU194779A (en) | 1983-10-31 |
| PH15530A (en) | 1983-02-09 |
| GR73839B (enExample) | 1984-05-04 |
| CS219256B2 (en) | 1983-03-25 |
| EP0008408A1 (en) | 1980-03-05 |
| EP0008408B1 (en) | 1981-12-09 |
| DK153844B (da) | 1988-09-12 |
| IL57923A (en) | 1982-09-30 |
| YU41170B (en) | 1986-12-31 |
| ES483289A1 (es) | 1980-09-01 |
| CA1116597A (en) | 1982-01-19 |
| ZA793909B (en) | 1980-10-29 |
| DK336779A (da) | 1980-02-12 |
| AU529068B2 (en) | 1983-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU850003A3 (ru) | Способ получени -метиловых сложныхэфиРОВ гидАНТОиНА | |
| EP0391766B1 (fr) | Nouveaux ligands macrocycliques azotés, procédé de préparation, complexes métalliques formés par ces ligands, composition de diagnostic et composition thérapeutique les contenant | |
| JPS63152382A (ja) | ピラノインドリジン誘導体及びその製造法 | |
| SU510999A3 (ru) | Способ получени (метоксиметил-фурилметил)6,7-бензоморфанов илиморфинанов | |
| PL141830B1 (en) | Method of obtaining novel derivatives of dihydropyridine | |
| EP0008408B1 (en) | 1,2,3,5-tetrahydroimidazothienopyrimidin-2-ones, a process for their preparation and pharmaceutical compositions | |
| EP0351255B1 (fr) | Dérivés de [(pipéridinyl-4)méthyl]-2 tétrahydro-1,2,3,4 isoquinoléine, leur préparation et leur application en thérapeutique | |
| SU1433409A3 (ru) | Способ получени производных 2- @ (аминоалкил)амино @ -1-фенилалканола-1 или их фармакологически приемлемых солей | |
| US5498711A (en) | Synthesis of 4,10-dinitro-2,6,8,12-tetraoxa-4,10-diazatetracyclo[5.5.0.05,903,11]dodecane | |
| DE2106694C2 (de) | Phthalimidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| CA1245654A (en) | Process for preparing novel n-substituted derivatives of 1-(4'-alkylsulfonylphenyl)-2-amino-1,3- propanediol | |
| US3139455A (en) | Phenoxyacetamidoximes | |
| BR0013750B1 (pt) | Intermediários para a produção de derivados de ácido naftiridina-3-carboxílico | |
| US3962237A (en) | 1 (h)-1,2,4-triazole derivatives | |
| SU368752A1 (enExample) | ||
| US4341789A (en) | Cycloaliphatic prostaglandin analogues | |
| US4735943A (en) | Eburnamonine oxime derivatives, salts thereof, and pharmaceutical agents containing the same | |
| SU493067A3 (ru) | Способ получени фенилимидазолидинонов | |
| IL25315A (en) | O-(2-guanidino-ethyl)-oximes | |
| PL100316B1 (pl) | Sposob wytwarzania nowych pochodnych indolopirydonaftyrydyny | |
| US3637853A (en) | O o'-bis(gamma-dimethylamino-propyl)-diisoeugenol and salts thereof | |
| Fabbri et al. | Binaphthyl-Substituted Chiral Phosphines and Oxides from Binaphthophooles and Nucleophiles | |
| JPS5942359A (ja) | スルホン類の製造法 | |
| US4119726A (en) | Cyclic exo amides | |
| US4189444A (en) | Process for the preparation of N,N'-disubstituted 2-naphthaleneethanimidamide and intermediates used therein |